Related Experiment Videos
P300 and symptom improvement in schizophrenia
J Gallinat1, M Riedel, G Juckel
1Department of Psychiatry, Laboratory of Clinical Psychophysiology, Free University Berlin, Eschenallee 3, 14050 Berlin, Germany. gallinat@zedat.fu-berlin.de
Psychopharmacology
|October 31, 2001
Summary
Auditory evoked P300 subcomponents, not single electrode P300, reflect positive symptom changes in schizophrenia. This finding suggests P300 subcomponents may offer reliable insights into schizophrenia pathophysiology and treatment response.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Psychology
Background:
- Reduced P300 amplitude is a potential trait marker for schizophrenia.
- Evidence suggests P300 amplitude also has state-dependent characteristics related to psychopathology.
Purpose of the Study:
- Investigate trait and state aspects of P300 amplitude in schizophrenia.
- Examine the influence of symptom improvement and atypical antipsychotics on P300 subcomponents longitudinally.
Main Methods:
- Recorded P300 in 17 schizophrenic patients and 17 healthy controls.
- Administered clozapine or olanzapine in a double-blind design for 4 weeks.
- Analyzed parietal and frontal P300 subcomponents using dipole source analysis.
Main Results:
- Schizophrenic patients showed reduced parietal P300 subcomponent amplitudes compared to controls.
- P300 subcomponent amplitudes did not change significantly over 4 weeks despite clinical improvement.
- Pronounced improvement in positive symptoms correlated with a slight enhancement of P300 subcomponents.
Conclusions:
- P300 subcomponents are modulated by positive symptom changes, not negative symptoms or specific neuroleptics.
- Dipole source analysis of P300 subcomponents may be more reliable than single electrode measurements.
- Findings support a model with two pathophysiological subgroups of schizophrenia.